Compare VNO & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNO | AMRX |
|---|---|---|
| Founded | 1946 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.4B |
| IPO Year | 1994 | 2018 |
| Metric | VNO | AMRX |
|---|---|---|
| Price | $32.87 | $19.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $39.38 | $22.71 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 10400.00 | 157.89 |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $1,810,425,000.00 | N/A |
| Revenue This Year | $0.86 | $4.53 |
| Revenue Next Year | $6.92 | $9.13 |
| P/E Ratio | ★ N/A | $52.01 |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $24.57 | $9.92 |
| 52 Week High | $41.60 | $21.18 |
| Indicator | VNO | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 47.30 |
| Support Level | $28.48 | $16.59 |
| Resistance Level | $34.83 | $19.26 |
| Average True Range (ATR) | 0.90 | 0.62 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 30.40 | 11.78 |
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.